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ABSTRACT
Objective: Nitroaromatic/nitrophenols have been widely distributed in nature and are mostly isolated from marine microorganisms and had shown 
a broad spectrum of antimicrobial activities against a wide range of microbial pathogens. The objective of the present work is to synthesize some new 
1,2,3-triazole-tethered nitroguaiacol ethers and evaluated of their antibacterial and antifungal activities.
Methods: A focused library of 1,2,3-triazole-tethered nitroguaiacol ethers was prepared by employing Cu (I) catalyzed click chemistry reaction and 
evaluated for their antimicrobial activities by broth microdilution method.
Results: Among the tested compounds, compounds 8e, 8f, 8g, and 8i exhibited broad-spectrum activity against selected pathogenic strains, with the 
MIC of 8 µg/mL for Gram-positive bacteria (Staphylococcus aureus), 16 µg/mL for Pseudomonas aeruginosa (Gram-negative bacteria), and Candida 
species, respectively.
Conclusion: Future investigations with this class of compounds may lead to the development of potential candidates for antimicrobial drug discovery.
Keywords: Nitroguaiacol, 1,2,3-triazoles, Antibacterial, Antifungal.
INTRODUCTION
The escalating resistance of currently available antibiotics demands 
the development of new molecular entities to counterpart infectious 
deceases [1]. Nitroaromatic/nitrophenols have been widely distributed 
in nature and are mostly isolated from marine microorganisms. They had 
shown a broad spectrum of antimicrobial activities against a wide range 
of microbial pathogens [2]. Nitrophenol derivatives have been known 
for their antimicrobial activities over the years [3]. 4-Nitrocatechol 
and other derivatives of catechol were found to be active against 
a panel of intestinal bacteria [4]. 4,6-Dinitroguaiacol and isomeric 
3,5-dinitroguaiacol isolated from the red algae Marginisporum aberrans 
showed antimicrobial activity against Bacillus subtilis [3,5]. Guaiacol is a 
naturally occurring phenolic compound which has gained attention due 
to their various synthetic applications. Nitroguaiacol ether derivatives 
have been found to display potential antibacterial activities [6].
On the other hand, 1,2,3-triazoles attained great attention 
due to their broad spectrum of biological activities including 
antimicrobial [7,8], anti-inflammatory [9,10], analgesic [10], 
anticancer [7,11-16], antitubercular [17-19], local anesthetic [9], 
immunomodulatory [20], antimalarial [8,21,22], anti-HIV [7,23-25], 
antileishmanial [26], and antiviral [7] activities. It has become an 
adjuvant ligand in drug discovery, which has been conjugated to 
improve the biological properties of molecules. 1,2,3-Triazole moieties 
are the versatile connecting units which are stable to metabolic 
degradation conditions and capable of making hydrogen bonds, which 
can be favorable in the binding of bimolecular targets and can improve 
the solubility [27,28]. Thus, 1,2,3-triazoles have emerged as powerful 
pharmacophores on their own right [29,30].
After the extensive work on triazole chemistry with respect to the 
antimicrobial drug development, 1,2,3-triazole-containing β-lactam 
antibiotics tazobactam (4) and cephalosporins cefatrizine (5) are in 
the market and some are in pipeline [8]. 1,2,3-Triazole-containing 
fluconazole analogs (6 and 7) were found to be potential antifungal 
agents against Candida fungal pathogens than control drugs fluconazole 
and amphotericin B [31].
Keeping in view the antimicrobial properties of nitroguaiacol and 
1,2,3-triazole moieties, a focused library of 1,2,3-triazole-tethered 
nitroguaiacol ethers (8a-8l) has been designed by applying “hybrid 
conjugation of bioactive ligands” strategy and synthesized by 
employing Cu (I) catalyzed 1,3-dipolar cycloaddition reactions between 
O-propargyl nitroguaiacol and substituted aromatic azides.
RESULTS AND DISCUSSION
Chemistry
1,2,3-Triazole-tethered nitroguaiacol ethers were synthesized and 
evaluated for their antibacterial and antifungal activities. As illustrated 
in Scheme 1, 1,2,3-triazole compounds were synthesized by the 
cycloaddition reaction of 2-methoxy-4-nitro-1-(prop-2-yn-1-yloxy) 
benzene 7 with various azides. Toward the synthesis of compound 
7, 2-methoxy-4-nitrophenol 5 was refluxed with propargyl bromide 
in dry acetone in the presence of potassium carbonate. Various 
substituted aromatic/sugar azides 8 were reacted with propargylated 
nitroguaiacol ether 7 under click chemistry reaction conditions to 
obtain the novel 1,2,3-triazole-tethered nitroguaiacol ethers 9a–9l 
in quantitative yields. Aromatic azides with varying substitutions 
including electron-withdrawing and electron-donating groups were 
reacted with compound 7.
A focused library of 12 compounds was synthesized (Table 1) by 
varying nature and cite of substitution on the aromatic ring attached 
to triazole moiety. All the synthesized triazoles were screened for their 
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Table 1: 1,2,3-Triazole-tethered nitroguaiacol ethers














antimicrobial activity. All the products were characterized by 1H NMR, 
13C NMR, IR, and ESI-MS. In the 1H NMR spectra, the formation of triazole 
was confirmed by the resonance of H–C of the triazole ring in the 
aromatic region (8.05–8.25 parts per million [ppm]). The structure was 
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further supported by the13C NMR spectra, which showed the C–atom 
signals corresponding to triazole derivatives at δ 142–148.
Biology
All the above-synthesized nitroguaiacols were tested for their in vitro 
antibacterial as well as antifungal activities against one reference of 
strains of each (total four strains) selected Gram-positive bacteria, 
Gram-negative bacteria, and Candida species by broth microdilution 
method following Clinical and Laboratory Standards Institute (CLSI) 
guidelines. The results are tabulated in Table 2.
Ciprofloxacin and amphotericin B served as drug control for bacterial 
strains and fungal strains, respectively. The results are representative 
of two separate experiments performed in duplicate and similar results 
were observed each time.
Compounds 8e, 8f, 8g, and 8i exhibited broad-spectrum activity 
against a variety of selected pathogenic strains, with the minimum 
inhibitory concentration (MIC) of 8 µg/mL for Gram-positive bacteria 
(Staphylococcus aureus), 16 µg/mL for Pseudomonas aeruginosa 
(Gram-negative bacteria), and Candida species, respectively. They have 
demonstrated significantly improved activities when compared to parent 
nitroguaiacol 9 (MICs ≥128 µg/mL). Among the compounds synthesized, 
halogen-substituted compounds were found to be active against S. aureus 
and moderately active against P. aeruginosa and fungal strains. Among the 
halogen-substituted compounds, -chloro, -fluoro, and trifluoromethyl-
substituted compounds demonstrated good activities. Regarding the 
position of substitution, para-position has mostly shown good activity. 
Compounds substituted with strong electron-withdrawing groups such 
as –NO2 and  –CN groups and electronic-donating groups such as –OCH3 
and –C2H5 are found to be either moderately active or inactive.
CONCLUSION
A focused library of 1,2,3-triazole-linked nitroguaiacol ethers was 
prepared by employing Cu (I) catalyzed click chemistry reaction and 
all the synthesized compounds were evaluated for their antimicrobial 
activities. Among the synthesized compounds, halogen-substituted 
compounds were demonstrated good-to-moderate activities against 
both Gram-positive and Gram-negative bacteria and fungal strains. 




All commercial chemicals used as starting materials and reagents 
in this study were purchased from Merck (India), Spectrochem, and 
Sigma-Aldrich which were of reagent grade. All melting points were 
uncorrected and measured using Electrothermal IA 9100 apparatus 
(Shimadzu, Japan); infrared (IR) spectra were recorded on Bruker 
ALPHA Fourier transform IR spectrometer (Germany), 1H-NMR spectra 
were determined on an Agilent (400 MHz) spectrometer and chemical 
shifts were expressed as ppm against TMS as internal reference. Mass 
spectra were recorded on 70 eV (EI Ms–QP 1000 EX, Shimadzu, Japan), 
column chromatography was performed on (Merck) Silica gel 60 
(particle size 0.06–0.20 mm).
Synthesis of 2-methoxy-4-nitro-1-(prop-2-yn-1-yloxy)benzene (11)
In a dry two neck round-bottomed flask equipped with a condenser, 
to the acetone solution of nitroguaiacol 9 (4.83 mmol), was added 
activated K2CO3 (24.14 mmol) and stirred for 10 min at room 
temperature under anhydrous condition. Then, propargyl bromide 
10 (5.79 mmol) was added to the reaction mixture and the reaction 
mixture was heated to reflux and continued to stir for 12 h. After the 
completion of the reaction monitored by thin-layer chromatography 
(TLC), the reaction mixture was quenched with excess of water 
(50 mL) and the product was extracted with ethyl acetate (50 mL×2). 
The combined organic layer was dried over anhydrous sodium sulfate, 
filtered, and evaporated under reduced pressure to afford the crude 
product which was recrystallized with ethyl acetate/hexane to afford 
the pure compound 11 in quantitative yields.
2-methoxy-4-nitro-1-(prop-2-yn-1-yloxy)benzene (11)
M.P. 118.6°C; IR (KBr) (cm–1): 3116, 2366, 2348, 1827, 1730, 1713, 
1694, 1680, 1669, 1633, 1613, 1588 1569, 1553, 1534, 1515, 1504, 
1468, 1453, 1377, 1340, 1280, 1232, 1136, 1082, 1016, 872, 806, 
752; 1H NMR (CDCl3, 400 MHz) δ (ppm): 2.56 (s, 1H), 3.93 (s, 3H), 4.84 
(s, 2H), 7.05 (d, 1H, J=8.80 Hz), 7.73 (s, 1H), 7.87 (d, 1H, J=8.80 Hz); 13C 
NMR (CDCl3, 100 MHz): δ 56.31, 56.84, 106.83, 112.19, 117.29, 142.22, 
149.36, 152.10; ESIMS: 207 (M+), 208 (M++1).
and the reaction mixture was stirred for 5 min. Reaction mixture was 
Table 2: In vitro antimicrobial activity of nitroguaiacol









9 >128 >128 >128 >128
11 >128 >128 >128 >128
8a 32 128 128 128
8b 32 128 128 128
8c 16 64 64 32
8d 16 64 64 32
8e 8 16 16 16
8f 8 16 16 16
8g 8 16 16 16
8h 32 >128 128 128
8i 8 16 16 16
8j 16 64 32 32
8k >128 >128 >128 >128
8l 64 >128 >128 >128
Ciprofloxacin 0.25 0.25 NT NT
Amphotericin B NT NT 0.5 0.5
NT: Not tested, MIC: Minimum inhibitory concentration, ATCC: American Type Culture Collection
Scheme 1: Synthesis of 1,2,3-triazole-tethered nitroguaiacol 
ethers
General  procedure  for  the  synthesis  of  1,2,3-triazoles  (Click  Chemistry)
Compound 2 was dissolved in 20 mL of tert-Butanol:water 
(1:1) solvent at  ambient temperature and then was charged 
CuSO4.5H2O 
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light blue in color. Then, sodium ascorbate was added at once to the 
reaction mixture and allowed to stir for 15 min. Reaction mixture color 
was changed to dark yellow. After 15 min, azide was added at once. 
The reaction mixture was allowed to stir for further 8 h at ambient 
temperature. After the completion of the reaction, monitored by TLC, 
reaction mixture was quenched with water and extracted with ethyl 
acetate. Combined organic layers were dried over anhydrous sodium 




M.P. 195.7°C; IR (KBr) (cm–1): 3116, 2366, 2348, 1827, 1730, 1713, 
1694, 1680, 1669, 1633, 1613, 1588 1569, 1553, 1534, 1515, 1504, 
1468, 1453, 1377, 1340, 1280, 1232, 1136, 1082, 1016, 872, 806, 752; 
1H NMR (CDCl3, 400 MHz) δ (ppm): 3.95 (s, 3H), 5.46 (s, 2H), 7.17 (d, 1H, 
J=9.20 Hz), 7.73–7.77 (m, 2H), 7.88–7.90 (dd, 1H, J=9.20 and 2.80 Hz), 
8.16–8.18 (dd, 1H, J=8.00 and 1.20 Hz), 8.23 (s, 1H), 8.30–8.32 (dd, 1H, 
J=8.40 and 1.20 Hz), 8.58 (t, 1H, J=1.60 Hz); 13C NMR (CDCl3, 100 MHz): 
δ 56.33, 62.88, 106.91, 112.11, 115.34, 117.54, 121.29, 123.46, 125.99, 
131.07, 137.51, 142.21, 148.97, 149.32, 152.76; ESIMS: 372 (M++1), 
394 (M++Na); Anal. Calcd. for C16H13N5O6: C, 51.76; H, 3.53; N, 18.86%, 
Found: C, 51.77; H, 3.54; N, 18.82%.
4-((2-methoxy-4-nitrophenoxy)methyl)-1-(4-nitrophenyl)-1H-1,2,3-
triazole (8b)
M.P. 226.7°C; IR (KBr) (cm–1): 3132, 2359, 2338, 1729, 1712, 1693, 
1679, 1668, 1644, 1631, 1594, 1569, 1552, 1513, 1467, 1374, 1341, 
1275, 1256, 1097, 1046, 863, 737, 685, 635; 1H NMR (CDCl3, 400 MHz) 
δ (ppm): 3.95 (s, 3H), 5.46 (s, 2H), 7.18 (d, 1H, J=8.80 Hz), 7.76 (s, 1H), 
7.90 (d, 1H, J=7.60 Hz), 7.97 (d, 2H, J=8.00 Hz), 8.21 (s, 1H), 8.41 (d, 2H, 
J=8.00 Hz); 13C NMR (CDCl3, 100 MHz): δ 56.33, 62.85, 106.93, 112.14, 
117.55, 120.62, 121.21, 125.57, 131.91, 140.88, 147.47, 152.71, 152.88; 
ESIMS: 372 (M++1), 394 (M++Na); Anal. Calcd. for C16H13N5O6: C, 51.76; 
H, 3.53; N, 18.86%, Found: C, 51.79; H, 3.50; N, 18.88%.
1-(2-chlorophenyl)-4-((2-methoxy-4-nitrophenoxy)methyl)-1H-1,2,3-
triazole (8c)
M.P. 120.4°C; IR (KBr) (cm–1): 3055, 2918, 2353, 2199, 1865, 1823, 
1789, 1763, 1730, 1714, 1694, 1644, 1585, 1568, 1518, 1453, 1415, 
1339, 1289, 1231, 1171, 1093,1032, 865, 795, 753, 711,642, 544, 447; 
1H NMR (CDCl3, 400 MHz) δ (ppm): 3.93 (s, 3H), 5.47 (s, 2H), 7.21 (d, 
1H, J=8.80 Hz), 7.41–7.47 (m, 2H), 7.55–7.61 (m, 2H), 7.74 (d, 1H, 
J=2.40 Hz), 7.87–7.90 (dd, 1H, J=8.80 and 2.00 Hz), 8.10 (s, 1H); 13C 
NMR (CDCl3, 100 MHz): δ 56.31, 63.06, 106.88, 112.38, 117.58, 125.33, 
127.74, 127.97, 130.81, 130.96, 134.65, 142.06, 142.69, 149.36, 153.01; 
ESIMS: 361 (M+), 362 (M++1), 363 (M++2), 383 (M++Na); Anal. Calcd.for 
C16H13ClN4O4: C, 53.27; H, 3.63; Cl, 9.83; N, 15.53 %, Found: C, 53.26; H, 
3.65; Cl, 9.81; N, 15.54%.
1-(3-chlorophenyl)-4-((2-methoxy-4-nitrophenoxy)methyl)-1H-1,2,3-
triazole (8d)
M.P. 142.6°C; IR (KBr) (cm–1): 3147, 3091, 2941, 2937, 2179, 1843, 
1819, 1788, 1730, 1713, 1694, 1681, 1593, 1551, 1517, 1465, 1402, 
1385, 1371, 1337, 1279, 1231, 1140, 989, 873, 849, 806, 788, 745, 678, 
641; 1H NMR (CDCl3, 400 MHz) δ (ppm): 3.94 (s, 3H), 5.44 (s, 2H), 7.18 
(d, 1H, J=8.80 Hz), 7.41–7.48 (m, 2H), 7.62 (d, 1H, J=7.60 Hz), 7.74–7.76 
(m, 2H), 7.87–7.90 (dd, 1H, J=8.80 and 2.40 Hz), 8.10 (s, 1H); 13C NMR 
(CDCl3, 100 MHz): δ 56.31, 62.94, 106.86, 112.11, 117.58, 118.56, 
120.87, 121.39, 129.13, 130.89, 135.69, 137.63, 142.10, 149.27, 152.86; 
ESIMS: 361 (M+), 362 (M++1), 363 (M++2), 383 (M++Na); Anal. Calcd. for 
C16H13ClN4O4: C, 53.27; H, 3.63; Cl, 9.83; N, 15.53 %, Found: C, 53.28; H, 
3.61; Cl, 9.85; N, 15.57%.
1-(4-chlorophenyl)-4-((2-methoxy-4-nitrophenoxy)methyl)-1H-1,2,3-
triazole (8e)
M.P. 152.4°C; IR (KBr) (cm–1): 3138, 3092, 2919, 2354, 2198, 1864, 
1823, 1789, 1746, 1729, 1713, 1694, 1665, 1644, 1587, 1551, 1514, 
1457, 1408, 1345, 1278, 1278, 1227, 1136, 1094, 1025, 774, 739, 628; 
1H NMR (CDCl3, 400 MHz) δ (ppm): 3.93 (s, 3H), 5.43 (s, 2H), 7.18 (d, 
1H, J=8.80 Hz), 7.49 (d, 2H, J=8.80 Hz), 7.66 (d, 2H, J=8.80 Hz), 7.74 (d, 
1H, J=2.40 Hz), 7.87–7.89 (dd, 1H, J=8.80 and 2.40 Hz), 8.08 (s, 1H); 13C 
NMR (CDCl3, 100 MHz): δ 56.31, 63.06, 106.88, 112.38, 117.58, 125.33, 
127.74, 127.97, 130.81, 130.96, 134.65, 142.06, 142.69, 149.36, 153.01; 
ESIMS: 361 (M+), 362 (M++1), 363 (M++2), 383 (M++Na); Anal. Calcd. for 
C16H13ClN4O4: C, 53.27; H, 3.63; Cl, 9.83; N, 15.53 %, Found: C, 53.24; H, 
3.66; Cl, 9.84; N, 15.54%.
Fig. 1: Hybrid conjugation of bioactive ligand
Fig. 2: Structure–activity relationship of 1,2,3-triazole-tethered 
nitroguaiacol ethers
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1-(2-fluorophenyl)-4-((2-methoxy-4-nitrophenoxy)methyl)-1H-1,2,3-
triazoletriazole (8f)
M.P. 130.6°C; IR (KBr) (cm–1): 3166, 2949, 2843, 2333, 2198, 1864, 
1842, 1823, 1789, 1769, 1748, 1731, 1714, 1699, 1644, 1634, 1590, 
1550, 1518, 1472, 1410, 1370, 1338, 1282, 1229, 1141, 1098, 864, 804, 
758, 711, 635; 1H NMR (CDCl3, 400 MHz) δ (ppm): 3.93 (s, 3H), 5.47 (s, 
2H), 7.21 (d, 1H, J=8.80 Hz), 7.34–7.47 (m, 2H), 7.58–7.63 (m, 2H), 7.74 
(d, 1H, J=2.40 Hz), 7.87–7.90 (dd, 1H, J=8.80 and 2.00 Hz), 8.12 (s, 1H); 
ESIMS: 345 (M++1), 367 (M++Na); Anal. Calcd.for C16H13FN4O4: C, 55.82; 
H, 3.81; F, 5.52; N, 16.27 %, Found: C, 55.79; H, 3.83; F, 5.51, N, 16.29%.
1-(4-fluorophenyl)-4-((2-methoxy-4-nitrophenoxy)methyl)-1H-1,2,3-
triazoletriazole (8g)
M.P. 120.5°C; IR (KBr) (cm–1): 3161, 3093, 2909, 2342, 2202, 1865, 
1841, 1823, 1789, 1769, 1730, 1714, 1694, 1644, 1587, 1568, 1550, 
1517, 1463, 1391, 1371, 1341, 1281, 1261, 1233, 1048, 1025, 869, 
838, 803, 774, 639, 616; 1H NMR (CDCl3, 400 MHz) δ (ppm): 3.93 (s, 
3H), 5.43 (s, 2H), 7.18–7.22 (m, 3H), 7.67–7.70 (m, 2H), 7.74 (d, 1H, 
J=1.60 Hz), 7.86–7.89 (dd, 1H, J=8.80 and 2.00 Hz), 8.05 (s, 1H); 13C 
NMR (CDCl3, 100 MHz): δ 56.31, 62.95, 106.83, 112.10, 116.68, 116.91, 
117.58, 121.61, 122.59, 122.68, 133.09, 142.06, 143.70, 149.25, 152.91, 
161.34, 163.82; ESIMS: 345 (M++1), 346 (M++2), 367 (M++Na); Anal. 
Calcd. for C16H13FN4O4: C, 55.82; H, 3.81; F, 5.52; N, 16.27 %, Found: C, 
55.83; H, 3.78; F, 5.51; N, 16.31%.
1-(4-bromophenyl)-4-((2-methoxy-4-nitrophenoxy)methyl)-1H-1,2,3-
triazoletriazole (8h)
M.P. 166.4°C; IR (KBr) (cm–1): 3141, 3090, 2938, 2360, 2328, 1948, 
1729, 1688, 1681, 1643, 1587, 1499, 1453, 1408, 1385, 1369, 1283, 
1228, 1173, 1021, 981, 843, 818, 799, 729, 628; 1H NMR (CDCl3, 400 
MHz) δ (ppm): 3.94 (s, 3H), 5.44 (s, 2H), 7.19 (d, 1H, J=8.80 Hz), 
7.59–7.66 (m, 4H), 7.74 (d, 1H, J=2.40 Hz), 7.87–7.90 (dd, 1H, J=8.80 
and 2.40 Hz), 8.09 (s, 1H); 13C NMR (CDCl3, 100 MHz): δ 56.32, 62.93, 
106.83, 112.10, 117.58, 121.27, 121.98, 122.78, 132.99, 135.75, 142.09, 
143.87, 149.23, 152.87; ESIMS: 405 (M+), 407 (M++2), 427 (M++Na), 429 
(M++2+Na); Anal. Calcd. for C16H13BrN4O4: C, 47.43; H, 3.23; Br, 19.72; N, 
13.83 %, Found: C, 47.45; H, 3.24; Br, 19.69; N, 13.84%.
4-((2-methoxy-4-nitrophenoxy)methyl)-1-(4-(trifluoromethyl)phenyl)-
1H-1,2,3-triazole (8i)
M.P. 128.3°C; IR (KBr) (cm–1): 3147, 3093, 2840, 2353, 2198, 1864, 
1823, 1789, 1761, 1748, 1730, 1717, 1694, 1644, 1588, 1551, 1519, 
1401, 1341, 1282, 1235, 1174, 1101, 1027, 865, 801, 739, 691, 683; 1H 
NMR (CDCl3, 400 MHz) δ (ppm): 3.94 (s, 3H), 5.44 (s, 2H), 7.18 (d, 1H, 
J=8.80 Hz), 7.65–7.75 (m, 3H), 7.87–7.90 (dd, 1H, J=8.80 and 2.40 Hz), 
7.94 (d, 1H, J= 7.60 Hz), 8.00 (s, 1H), 8.17 (s, 1H); 13C NMR (CDCl3, 100 
MHz): δ 56.31, 62.92, 106.91, 112.15, 117.56, 121.34, 123.63, 125.65, 
130.62, 137.14, 142.15, 144.14, 149.30, 152.85; ESIMS: 395 (M++1); 
Anal. Calcd. for C17H13F3N4O4: C, 51.78; H, 3.32; F, 14.45; N, 14.21 %, 
Found: C, 51.81; H, 3.32; F, 14.47; N, 14.19%.
4-(4-((2-methoxy-4-nitrophenoxy)methyl)-1H-1,2,3-triazol-1-yl)
benzonitrile (8j)
M.P. 179.6°C; IR (KBr) (cm–1): 2927, 2227, 1866, 1838, 1822, 1783, 
1730, 1713, 1694, 1644, 1588, 1551, 1505, 1444, 1394, 1370, 1333, 
1279, 1222, 1178, 1094, 1017, 839, 800, 739, 639; 1H NMR (CDCl3, 400 
MHz) δ (ppm): 3.94 (s, 3H), 5.45 (s, 2H), 7.17 (d, 1H, J=9.20 Hz), 7.74 
(d, 1H, J=2.00 Hz), 7.83 (d, 2H, J=8.00 Hz), 7.87–7.91 (m, 3H), 8.18 (s, 
1H); 13C NMR (CDCl3, 100 MHz): δ 51.57, 58.11, 102.18, 107.40, 108.09, 
112.79, 115.54, 115.92, 116.33, 124.43, 129.20, 134.81, 137.47, 139.71, 
144.56, 148.01; ESIMS: 352.20 (M++1), 353 (M++2), 374 (M++Na), 375 
(M++1+Na); Anal. Calcd. for C17H13N5O4: C, 58.12; H, 3.73; N, 19.93%, 
Found: C, 58.09; H, 3.75; N, 19.94%.
1-(4-ethylphenyl)-4-((2-methoxy-4-nitrophenoxy)methyl)-1H-1,2,3-
triazole (8k)
M.P. 131.7°C; IR (KBr) (cm–1): 32955, 2923, 2796, 1633, 1614, 1574, 
1557, 1455, 1446, 1425, 1377, 1308, 1270, 1227, 1140, 1036, 989, 779, 
750; 1H NMR (CDCl3, 400 MHz) δ (ppm): 1.25 (t, 3H, J=7.60 Hz), 2.70 
(q, 2H, J=7.60 Hz), 3.94 (s, 3H), 5.43 (s, 2H), 7.22 (d, 1H, J=8.40 Hz), 
7.33 (d, 1H, J=8.00 Hz), 7.61 (d, 2H, J= 8.00 Hz), 7.74 (s, 1H), 7.88 (d, 
1H, J=6.80 Hz), 8.19 (s, 1H); 13C NMR (CDCl3, 100 MHz): δ 15.32, 18.43, 
56.31, 62.98, 106.83, 112.19, 117.60, 120.71, 129.16, 134.97, 142.02, 
145.54, 149.28, 153.01; ESIMS: 355 (M++1), 377 (M++Na); Anal. Calcd. 




M.P. 154.4°C; IR (KBr) (cm–1): 3144, 2964, 2392, 2187, 1847, 1824, 
1789, 1764, 1730, 1713, 1694, 1674, 1644, 1587, 1552, 1516, 1401, 
1370, 1343, 1277, 1222, 1096, 1024, 850, 801, 741, 633; 1H NMR 
(CDCl3, 400 MHz) δ (ppm): 3.86 (s, 3H), 3.93 (s, 3H), 5.45 (s, 2H), 7.06–
7.10 (m, 2H), 7.25 (d, 1H, J=8.40 Hz), 7.41 (t, 1H, J=8.00 Hz), 7.75 (t, 2H, 
J=7.60 Hz), 7.88 (d, 1H, J=9.20 Hz), 8.24 (s, 1H); 13C NMR (CDCl3, 100 
MHz): δ 55.96, 56.31, 62.98, 106.83, 112.30, 117.61, 121.27, 125.38, 
125.65, 130.27, 141.95, 149.30, 151.03, 153.19; ESIMS: 357 (M++1), 
379 (M++Na); Anal. Calcd. for C17H16N4O5: C, 57.30; H, 4.53; N, 15.72%, 
Found: C, 57.28; H, 4.53; N, 15.74%.
Biology
Microbial strains
One reference each of the following species was used for their in 
vitro susceptibility to nitroguaiacols in this study: S. aureus American 
Type Culture Collection (ATCC) 29213, P. aeruginosa ATCC 27853, 
Candida albicans ATCC 90028, and Candida parapsilosis ATCC 22019. 
These strains were procured from the ATCC, Manassas, VA, USA.
Antimicrobial susceptibility testing assays
The antibacterial and antifungal activities of the nitroguaiacols 
were performed by broth microdilution methods as per the 
guidelines of Clinical and Laboratory Standard Institute 
(CLSI M07–A8, 2008; CLSI M27–A3, 2008) [32,33]. Stock solutions 
were prepared in 100% dimethyl sulfoxide (DMSO); distilled water 
was used for ciprofloxacin), with a final DMSO concentration of 
1% (vol. per vol.) and 2-fold serial dilutions were prepared in 
media to yield twice the final concentration required for testing, 
which ranged from 128 to 0.25 µg/mL for nitroguaiacol and 8 to 
0.015 µg/mL for ciprofloxacin as well as amphotericin B. The final 
inoculum concentration of approximately 5×105 CFU/mL for bacteria 
(CLSI M07–A8, 2008) and approximately 2.5×103 CFU/mL for Candida 
species (CLSI M27–A3, 2008). Ciprofloxacin and amphotericin B 
served as the standard drug controls for bacterial and fungal strains, 
respectively. The microtiter plates were incubated at 35°C for 24 h 
for bacterial strains and 48 h for fungal strains. The plates were 
read visually and the MIC was defined as the lowest concentration 
of test sample that prevented visible growth with respect to the 
growth control. All experiments were conducted twice in duplicates 
on separate occasions with freshly prepared inoculums and stock 
solutions.
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